BLOOMBERG BUSINESSWEEK: A US company will next month report the results of its study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer, also called castration-resistant prostate cancer. READ MORE>
Posts Tagged ‘castration-resistant prostate cancer’
Trial begins on new antagonist drug that takes over after docetaxel-based chemotherapy
Posted in Chemotherapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, AFFIRM, cancer research, castration-resistant prostate cancer, docetaxel-based chemotherapy, drug MDV3100, MEDICAL NEWS TODAY, novel androgen receptor antagonist, phase 3 clinical trial, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on September 25, 2009| Leave a Comment »
MEDICAL NEWS TODAY: A phase 3 clinical trial of the investigational drug MDV3100 for advanced prostate cancer has just begun in the US. READ MORE>
Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with .
Dutch study looks at what causes prostate cancer to move to its deadly final stage
Posted in Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, bypass androgen-deprived conditions, castration-resistant prostate cancer, Dutch study, hormone refractory stage, Hormone therapy, hormone-naïve, molecular and cellular changes, prostablog, prostate, prostate blog, prostate treatment debate on August 3, 2009| Leave a Comment »
AUGUST 3: URO TODAY: An understanding of the mechanisms prostate cancer cells use to bypass androgen-deprived conditions, thus moving patients to the hormone refractory stage, is the aim of a new Dutch study. READ MORE>
Knowledge of the molecular and cellular changes that occur during the transition of hormone-naïve to castration-resistant prostate cancer is increasing rapidly. This might provide a window of opportunity for (future) drug development, and for treating patients with these potentially devastating states of disease.
PROSTATE RESEARCH: Study looks at management of castration-resistant patients
Posted in Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, cancer research, castration-resistant prostate cancer, docetaxel, Hormone therapy, paclitaxel-based chemotherapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on June 24, 2009| Leave a Comment »
JUNE 24: URO TODAY: Management of castration-resistant prostate cancer after docetaxel has become an unmet need for which various agents have been investigated. READ MORE>
PROSTATE RESEARCH: Study looks at efficacy of drug for castrate-resistant patients
Posted in Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment debate, Treatment news, tagged advanced prostate cancer, cancer research, castration-resistant prostate cancer, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, sunitinib, tyrosine kinase receptors, URO TODAY on June 19, 2009| Leave a Comment »
JUNE 19: URO TODAY: A new study has explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer. READ MORE>
PROSTATE TREATMENT: Drug leads to big PSA drop in castrate-reisistant patients
Posted in Hormone-refactory, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, tagged abiraterone acetate, advanced prostate cancer, cancer research, castration-resistant prostate cancer, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, prostate-specific antigen, PSA, PSA test, REUTERS HEALTH on June 19, 2009| 1 Comment »
Prostablog 